Induced pluripotent stem cells are the pluripotent stem cells that are generated through the introduction of four specific genes in the adult stem cells. These induced pluripotent stem cells offer a limitless supply of un-matured or stem cells for various therapeutic purposes.
Induced pluripotent stem cells are in deep R&D phase for its applications in drug development, disease modelling, and regenerative medicine. Since the induced pluripotent stem cells are produced directly from adult stem cells, they do not require embryos, thereby not being subject to various ethical considerations.
Induced pluripotent stem cells can be synthesized in patient matching similarity, and provides unlimited access to autologous cells for the transplantation procedures, neglecting the immune response or rejection factor. Induced pluripotent stem cells are mainly produced in mouse model, and from human fibroblast cells.
The additional cells such as renal epithelial cells and human keratinocytes are also used to produce induced pluripotent stem cells. A variety of genes are expressed in induced pluripotent stem cells which include Oct-3/4, Sox family, Klf family, Myc family, Nanog, Lin28, and Glis1.
Request for Table of Contents @ www.persistencemarketresearch.com/toc/17968
The overall growth of the induced pluripotent stem cells market is driven by increasing trends in the use of regenerative medicine in drug development coupled with the expansion of research and development of the stem cells on a global level. In addition, the diverse applications of induced pluripotent stem cells for disease modelling, drug development (patient-dependent drug efficacy), and many others are driving the growth of induced pluripotent stem cell market.
The increasing use of regenerative medicine utilizing induced pluripotent stem cells, also propels the market growth. For instance, according to the estimates of National Institutes of Health (NIH), more than 500,000 people had used regenerative medicine technology in U.S.
However, certain ethical issues among the population can hamper the growth of induced pluripotent stem cells market. The complications in the generation of induced pluripotent stem cells such as low efficiency, genomic insertion, tumorigenicity, and incomplete generation of stem cells, can hinder the global market of induced pluripotent stem cells.
Induced pluripotent stem cells market is expected to show an exponential growth during the forecast period. The induced pluripotent stem cells were introduced in 2006, and various technological advancements has been witnessed in recent years.
The benefits of these stem cells create lucrative opportunities for developing patient-specific therapies. However, standardization of protocols are not yet specified, and the procedure is too inadequate for clinical applications.
But in contrast to that, this technology is in its R&D phase, and various public and private organizations are investing to develop novel induced pluripotent stem cells.
Geographically, global induced pluripotent stem cells market can be segmented by region into North America, Latin America, Europe, Asia-Pacific and Middle East & Africa. North America is expected to hold the largest market share for induced pluripotent stem cells over the forecast period, followed by Europe owing to easy availability of highly developed technology protocols and standardizations of procedures.
In addition, these regions are equipped with a large population of skilled professionals, and better infrastructure, in addition to investment in research and development and hence, drives the growth of induced pluripotent stem cells market.
Asia-Pacific region is expected to be a high growth region over the forecast period owing to the increasing R&D ventures in countries such as Japan, China, and India, and increasing regulatory policies. However, the regions such as Latin America, Middle East, and Africa shows steady growth during the forecast period owing to the presence of limited healthcare infrastructure, and lack of skilled professionals.
Request a Sample Brochure of the Report @ www.persistencemarketresearch.com/samples/17968
Some of the market participants in the global induced pluripotent stem cells are BrightPath Biotherapeutics Co., Ltd, Biotime, Inc., Evotec AG, HipSci, and Fate Therapeutics, Inc.
Category: Market Research Publishers and RetailersCompany about: Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance. To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intel ...
For more information: